Sickle Cell Disease Linked to Higher Risk of Retinal Vascular Occlusion
HCPLive
AUGUST 1, 2024
Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
HCPLive
AUGUST 1, 2024
Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.
HCPLive
JUNE 13, 2024
Hydroxyurea treatment may impact seminal fluid levels and ovarian reserves in male and female patients with sickle cell disease.
Science Daily - Heart Disease
APRIL 11, 2024
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study.
Medical Xpress - Cardiology
APRIL 11, 2024
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology.
HCPLive
MARCH 25, 2024
Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.
HCPLive
APRIL 18, 2024
Elna Saah, MD joins HCPLive to discuss the current landscape in sickle cell disease and recent advancements benefiting clinical care.
HCPLive
DECEMBER 10, 2023
Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.
HCPLive
MARCH 12, 2024
The 2016 CDC guidelines led to significant decreases in opioid prescriptions and an increase in pain-related healthcare utilization for people with sickle cell disease.
HCPLive
FEBRUARY 16, 2024
Over the study period, pain screening procedures were integrated within routine clinical visits and providers’ workflow in sickle cell disease care.
HCPLive
MARCH 20, 2024
Results from the PHEDRE study show nitrous oxide in a gas mixture for pain was not problematic for most patients with sickle cell disease in France.
HCPLive
FEBRUARY 18, 2024
Hearing loss was more prevalent among children and adults with sickle cell disease and its traits compared to matched controls with normal hemoglobin.
HCPLive
DECEMBER 12, 2023
Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.
HCPLive
DECEMBER 11, 2023
A higher prevalence of STI diagnosis is observed in adolescents and young adults with sickle cell disease compared with controls.
HCPLive
DECEMBER 9, 2023
This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.
HCPLive
AUGUST 11, 2024
Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.
Med Page Today
MAY 11, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
Stroke Journal
FEBRUARY 1, 2024
Background:White matter disease is a common phenomenon in patients with sickle cell disease, that has been linked to cognitive impairment. However, there is no standardized approach for quantification of the cerebral disease burden. However, its utility in sickle cell disease has not yet been established.
HCPLive
MARCH 13, 2024
In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.
HCPLive
MARCH 27, 2024
A new analysis summarized evidence on the effects of allogeneic HSCT on SCD-related organ dysfunction in pediatric and adult patients with SCD.
HCPLive
FEBRUARY 21, 2024
A meta-analysis revealed a higher prevalence of abnormal ECG findings in individuals with SCD compared to those without the disease.
HCPLive
AUGUST 6, 2024
Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.
HCPLive
JUNE 20, 2024
Early detection from a universal newborn screening program in Canada significantly reduced disease-related burden in children with SCD.
HCPLive
FEBRUARY 19, 2024
No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.
HCPLive
DECEMBER 12, 2023
Final emergency department pain scores, opioid doses in the emergency department, and receipt of an opioid prescription at discharge predicted hospitalization and return visits.
HCPLive
JUNE 14, 2024
Phase 1/2/3 trial data show the investigational gene-editing medicine has been well-tolerated, with encouraging efficacy, for people living with SCD.
HCPLive
APRIL 15, 2024
A recent multi-center study identified risk factors linked to premature mortality in sickle cell disease, including male gender and hematologic and biochemical parameters.
Stroke Journal
FEBRUARY 1, 2024
Background:Microvascular thromboinflammation is a major pathomechanism underlying vaso-occlusive crisis in patients with sickle cell disease (SCD), yet its role underlying the elevated stroke risk in SCD is unclear. Stroke, Volume 55, Issue Suppl_1 , Page ATMP7-ATMP7, February 1, 2024.
HCPLive
APRIL 11, 2024
In a nationwide study of an adult SCD population, the risk of mortality increased with the number of HVOCs in the year before death.
HCPLive
APRIL 3, 2024
Our March 2024 month-in-review in hematology features updates to the anemia pipeline, the latest research in sickle cell disease, and the role of SGLT2 inhibition on hematologic outcomes.
HCPLive
JUNE 17, 2024
The CRISPR-based gene therapy demonstrated durable effects on SCD and TDT, with the longest follow-up extending past 5 years.
Stroke Journal
FEBRUARY 1, 2024
Background:Large-vessel vasculopathy (LVV), such as moyamoya syndrome, increases stroke risk with sickle cell disease (SCD). Stroke, Volume 55, Issue Suppl_1 , Page ATMP12-ATMP12, February 1, 2024.
HCPLive
APRIL 28, 2024
Preliminary findings demonstrate an improvement in eGFR slope in nearly all patients with SCD after treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
HCPLive
FEBRUARY 26, 2024
An ancillary study of the phase 2 HOPE-KIDS 1 trial revealed voxelotor is associated with reduced sickling and hemolysis in children with SCD.
HCPLive
FEBRUARY 20, 2024
Voxelotor decreases oxygen extraction fraction and cerebral blood flow towards levels observed in healthy children.
The American Journal of Cardiology
AUGUST 10, 2024
Publication date: Available online 10 August 2024 Source: The American Journal of Cardiology Author(s): Min-Jung Kim, Grace Lee, Gian Lima, Osama Mukarram, Samuel Crooks, Kristin Marshall, Agnes S.
HCPLive
JULY 14, 2024
A study from the ASH Research Network reports positive antibody response and tolerability after mRNA vaccination in people with sickle cell disease.
HCPLive
MAY 14, 2024
Age and sickle cell disease genotype predicted individuals with sickle cell retinopathy at risk for proliferative disease.
HCPLive
DECEMBER 10, 2023
Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.
HCPLive
MAY 2, 2024
Our April month in review for hematology breaks down the latest updates to the pipeline, mortality risk in people with sickle cell disease, and our newest multimedia offerings.
HCPLive
APRIL 9, 2024
A systematic review and meta-analysis of HSCT in children with sickle cell disease demonstrated pooled survival rates exceeding 90%.
HCPLive
DECEMBER 12, 2023
Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.
HCPLive
DECEMBER 10, 2023
These findings presented at ASH show promise for future studies on GBT02601 as a potential alternative to voxelotor for sickle cell disease.
HCPLive
DECEMBER 14, 2023
Keli Coleman, MD, discusses findings from her research about the role of pain scores and opioids in predicting hospitalization and return visits in children with sickle cell disease and uncomplicated pain crises.
Stroke Journal
FEBRUARY 1, 2024
We review the results of 9 patients who were evaluated with digital subtraction angiography (DSA), including 2 patients receiving different multiple drug regimens of acute intra-arterial therapies. One patient was also found eligible and treated with IV-thrombolysis.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content